The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2
Open accessPublished version of a preprint
Abstract
A decoy to neutralize SARS-CoV-2: Many efforts to develop therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are focused on the interaction between the spike protein, which decorates the surface of the virus, and its host receptor, human angiotensin-converting enzyme 2 (hACE2). Linsky et al. describe a de novo design strategy that allowed them to engineer decoy proteins that bind to the spike protein by replicating the hACE2 interface. The best decoy, CTC-445, bound with low nanomolar affinity, and selection of viral mutants that decrease binding is unlikely because this would also affect binding to hACE2. A bivalent version of CTC-445 bound even more tightly, neutralized SARS-CoV-2 infection of cells, and protected hamsters from a SARS-CoV-2 challenge. The stable decoy has the potential for respiratory therapeutic delivery. Science , this issue p. 1208
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Design and characterization of de novo ACE2 decoys. (A) ACE2 (gray) and its binding motifs (H1 19-52, orange; H2 55-84, green; EE3 346-360, blue) in complex with SARS-CoV-2 RBD (pink). Three starting structures were simultaneously used as targets (see main text); 6VW1 is shown. (B) De novo secondary structure elements (magenta) were computationally generated to stabilize H1, H2, and EE3. Seven combinations of secondary structure elements were considered. Circles are α-helices, triangles are β-sheets, filled circles are helices oriented forward, and empty circles are helices oriented backward. We used Rosetta to generate fully connected backbones (using the “protein_mimic_designer” algorithm) and amino acid sequences predicted to fold into the target structure. In all cases, the binding interface of ACE2 with the SARS-CoV-2 RBD was preserved intact (see the materials and methods). (C) Automatic computational filtering based on eight metrics selected the best candidates. The RMSD of the binding motifs to ACE2 was also used as a quality check. The dots indicate the mean computational score for each design scored against the three target RBD structures. Designs selected for experimental testing are shown in black. Our best design, CTC-445, is shown in red. The blue boxes indicate the filtering thresholds (see the materials and methods). (D) Designs that passed filtering were subjected to biased forward folding simulations (see the materials and methods), here shown for CTC-445, including the unsalted biased simulation (brown), the native-salted simulation (orange), and relaxation (blue). (E) The top 196 designs were selected for yeast display screening using a combination of Rosetta score per residue, the ddG Rosetta filter, and the folding simulations (see the materials and methods). The designs were individually assessed for specific binding to SARS-CoV-2 spike RBD (Fc fusion, 200 nM). The plot for CTC-445 is shown. (F) CTC-445 was recombinantly expressed and purified by affinity chromatography (see the materials and methods). Analytical size exclusion chromatography (SEC) for CTC-445 revealed the presence of oligomeric species. (G and H) CTC-445 was optimized by directed evolution and rational combination of the observed favorable mutations (G), leading to CTC-445.2 (SEC), which is mainly monomeric in solution (H) and ~1000× more potent to compete with ACE2 than its parent [see (G)]. We further optimized the potency of our molecule by generating a bivalent version named CTC-445.2d. (I) Potency of designs to outcompete binding of SARS-CoV-2 RBD to ACE2, as measured by competition enzyme-linked immunosorbent assay (ELISA) using a constant concentration of 0.4 nM ACE2. (J) Timeline of the de novo protein design and optimization pipeline. Timewise, green indicates phases that we believe were performed optimally, red indicates those that can potentially be avoided in future efforts, and yellow indicates phases that can potentially be expedited by using more advanced and/or automated methods for gene synthesis, cloning, and high-throughput screening.](https://figures.cochat.ai/paper-figures/623a08f217244b7cb8bd3e5130040cce/de-novo-design-of-potent-and-resilient-hace2-decoys-to-neutralize-sars-cov-2-figure-1.jpg)

![Fig. 3 Cryo-EM structure of the CTC-445.2–S complex. (A to D) Cryo-EM reconstructions of CTC-445.2 (blue) bound to soluble spike trimers (gray). 3D classification revealed four distinct classes: one CTC-445.2 bound to an “up” RBD (A), two CTC-445.2 bound to two “up” RBDs (B), two CTC-445.2 bound to one “up” and one “down” RBD (C), and three CTC-445.2 bound to two “up” and one “down” RBD (D). (E) Overlay of CTC-445.2-RBD computationally modeled (yellow) and experimentally determined using cryo-EM (blue). The Cα RMSD between the design model and the refined experimental structure is 1.1 Å. (F to H) Comparison of cryo-EM CTC-445.2 (blue), computationally modeled CTC-445.2 (yellow), and hACE2 (green) at the interface of the RBD (gray). (I) Deep mutational scanning heatmap showing the average effect on the enrichment for single site mutants of CTC-445.2 when assayed by yeast display for binding to the SARS-CoV-2 RBD (binding assayed at RBD concentrations of 100, 50, 25, 12.5, 6.25, 3.125, and 1.5625 pM; see the materials and methods). (J) Design model of CTC-445.2 colored by average enrichment at each residue position [from the data in (I)] bound to SARS-CoV-2 RBD (gray). As expected, mutations in the core of the design or to positions involved in binding to the RBD are generally disallowed. The deep mutational scanning revealed that there is still room to further improve the binding affinity of CTC-445.2, including mutations in the binding interface that in principle could afford higher potency and selectivity at the cost of compromising the decoy’s mutational escape resiliency (see Fig. 4).](https://figures.cochat.ai/paper-figures/e55e77c56f884b099aff2cb45d34297d/de-novo-design-of-potent-and-resilient-hace2-decoys-to-neutralize-sars-cov-2-figure-3.jpg)
![Fig. 4 Resilience of CTC-445.2 to SARS-CoV-2 RBD mutational escape. (A) Deep mutational scanning (DMS) of the SARS-CoV-2 RBD interface was performed to assess the effect on binding (by yeast display) to CTC-445.2 (top) or hACE2 (bottom) at eight different concentrations (656, 218, 72, 24, 8, 2, 0.3, and 0.1 nM; fig. S16 and materials and methods). The heatmaps indicate the effect on binding for each possible single amino acid mutation in the hACE2-binding interface of the RBD (see the materials and methods). The results are the average over all the concentrations tested. A black square represents lack of expression in the naive (unselected) library. The color bars at the bottom indicate the secondary structure element with which a given RBD residue interacts: H1, orange; H2, green; EE3, blue; and H4, magenta. Approximately 1700 single mutations were targeted by the experiment. (B) The SARS-CoV-2 RBD surface is colored according to the per-residue-averaged enrichments for binding to CTC-445.2 (top) or hACE2 (bottom). For reference, the structure of CTC-445.2 or ACE2 (respectively) is shown in semitransparent gray cartoons. (C) The 2D scatter plots compare the enrichment values [as in (A)] for the DMS of the RBD binding to CTC-445.2 (y-axis) versus hACE2 (x-axis). There is a high correlation between the effect of RBD mutations in the binding of both molecules, demonstrating the mutational resilience of the de novo decoy (Pearson’s r = 0.92).](https://figures.cochat.ai/paper-figures/ded0c898f59c4bbd8b583f9c8dbd17f3/de-novo-design-of-potent-and-resilient-hace2-decoys-to-neutralize-sars-cov-2-figure-4.jpg)
![Fig. 5 In vitro virus neutralization by CTC-445.2d. (A) Top left: In vitro neutralization of NanoLuc SARS-CoV-2 by CTC-445.2d in Calu-3 cells after 72 hours of incubation at a MOI of 1.0. Top right: A cell viability assay (48 hours) confirmed that the decoys are not cytotoxic to Calu-3. Bottom left: In vitro neutralization of live BetaCoV/Hong Kong/VM20001061/2020 SARS-CoV-2 virus in Vero E6 cells at a MOI of 1.0. The cells were incubated with CTC-445.2d throughout infection and the colors indicate the following: orange, before infection, during infection, and after infection; black, after infection only; and gray, before infection only. SARS-CoV-2 RNA copy numbers were determined by quantitative real-time reverse transcription polymerase chain reaction. All assays were performed in triplicate unless otherwise noted, and all data points are shown. Bottom right: Cell viability in Vero E6 cells was independently performed (CCK8 assay) and it was confirmed that the de novo decoys are not cytotoxic. (B) In vivo mouse pharmacokinetics and tolerability of intranasally administered CTC-445.2d. Left: Plot showing the concentration of fully functional CTC-445.2d (i.e., capable of binding to the SARS-CoV-2 RBD; see the materials and methods) found in homogenized lungs of Balb/c mice after a single 100 μg dose, measured at various times after dosing (n = 5 mice). Right: Body weight of mice after repeat daily intranasal doses of CTC-445.2d (100 μg; n = 18 at day 0) compared with control [phosphate-buffered saline (PBS)–treated] mice (n = 5). At each time point, three CTC-445.2d–treated mice were sacrificed for lung examination. Weight data shown are for the remaining mice (n = 18, 15, 12, 9, 6, and 3 at days 1, 2, 4, 8, 11, and 14, respectively). No significant weight loss or lung abnormalities were observed. Error bars indicate the standard deviation. (C) In vivo Syrian hamster SARS-CoV-2 challenge. Left: Body weight measurements through day 10 for unchallenged hamsters (n = 5, red) compared with SARS-CoV-2–challenged hamsters treated either with a single dose of CTC-445.2d (day 0 at –12 hours; n = 8, orange) or PBS (day –1, day 0 at –12 hours, day 1, and day 2; n = 7, gray). Right: Survival plot. Hamsters were euthanized when they displayed clinical signs of distress according to protocol clinical scoring criteria (see the materials and methods). At the end of the experiment, all hamsters treated with the de novo decoy CTC-445.2d survived, exhibiting moderate weight loss, whereas hamsters treated with vehicle did not survive past day 7 because of severe weight loss and other complications from the viral infection (see table S5).](https://figures.cochat.ai/paper-figures/41c3c064f6944ee9a7976418bd6e3ec3/de-novo-design-of-potent-and-resilient-hace2-decoys-to-neutralize-sars-cov-2-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SciPy 1.0: fundamental algorithms for scientific computing in Python
Virtanen, P., Gommers, R., Oliphant, T. E., Haberland, M., Reddy, T., Cournapeau, D., Burovski, E., Peterson, P., Weckesser, W., Bright, J., et al. (2020) · Nature Methods · doi:10.1038/s41592-019-0686-2 · Cited by 38,430
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
SciPy 1.0: fundamental algorithms for scientific computing in Python
Virtanen, P., Gommers, R., Oliphant, T. E., Haberland, M., Reddy, T., Cournapeau, D., Burovski, E., Peterson, P., Weckesser, W., Bright, J., et al. (2019) · Apollo - University of Cambridge Repository · doi:10.17863/cam.64134 · Cited by 10,460
Enzymatic assembly of DNA molecules up to several hundred kilobases
Gibson, D. G., Young, L., Chuang, R.-Y., Venter, J. C., Hutchison, C. A., & Smith, H. O. (2009) · Nature Methods · doi:10.1038/nmeth.1318 · Cited by 9,996
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Automated electron microscope tomography using robust prediction of specimen movements
Mastronarde, D. N. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.07.007 · Cited by 5,336
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
Yan, R., Zhang, Y., Li, Y., Xia, L., Guo, Y., & Zhou, Q. (2020) · Science · doi:10.1126/science.abb2762 · Cited by 5,040
Research works printed but not linked: 1
- National Center for Biotechnology Information “VAST: Non-redundant PDB chain set” (2016); https://structure.ncbi.nlm.nih.gov/Structure/VAST/nrpdb.html.
Cited by
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Chen, J., Wang, R., Gilby, N. B., & Wei, G.-W. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01451 · Cited by 653
Self-citationCircular RNA Vaccines against SARS-CoV-2 and Emerging Variants
Qu, L., Yi, Z., Shen, Y., Lin, L., Chen, F., Xu, Y., Wu, Z., Tang, H., Zhang, X., Tian, F., et al. (2021) · doi:10.1101/2021.03.16.435594 · Cited by 636
“It has been reported that SARS-CoV-2 neutralizing nanobodies or 190 hACE2 decoys could inhibit the SARS-CoV-2 infection (54-56).”
Scaffolding protein functional sites using deep learning
Wang, J., Lisanza, S., Juergens, D., Tischer, D., Watson, J. L., Castro, K. M., Ragotte, R., Saragovi, A., Milles, L. F., Baek, M., et al. (2022) · Science · doi:10.1126/science.abn2100 · Cited by 487
“As a test case, we scaffolded the helix of human angiotensin-converting enzyme 2 (hACE2) interacting with the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (29).”
MethodDeep generative molecular design reshapes drug discovery
Zeng, X., Wang, F., Luo, Y., Kang, S.-G., Tang, J., Lightstone, F. C., Fang, E. F., Cornell, W., Nussinov, R., & Cheng, F. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100794 · Cited by 295
“65 Deep generative models can also be used to design protein therapies by modeling the spatial properties of the amino acid sequence.”
BackgroundDeveloping therapeutic approaches for twenty-first-century emerging infectious viral diseases
Meganck, R. M., & Baric, R. S. (2021) · Nature Medicine · doi:10.1038/s41591-021-01282-0 · Cited by 252
Self-citationWang, R., Chen, J., Gao, K., & Wei, G.-W. (2021) · Genomics · doi:10.1016/j.ygeno.2021.05.006 · Cited by 191
Self-citationCirculating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2
El-Shennawy, L., Hoffmann, A. D., Dashzeveg, N. K., McAndrews, K. M., Mehl, P. J., Cornish, D., Yu, Z., Tokars, V. L., Nicolaescu, V., Tomatsidou, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27893-2 · Cited by 195
Opportunities and challenges in design and optimization of protein function
Listov, D., Goverde, C. A., Correia, B. E., & Fleishman, S. J. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00718-y · Cited by 180
Endothelium Infection and Dysregulation by SARS-CoV-2: Evidence and Caveats in COVID-19
Bernard, I., Limonta, D., Mahal, L., & Hobman, T. (2020) · Viruses · doi:10.3390/v13010029 · Cited by 183
“hrsACE2 has recently been reported to reduce SARS-CoV-2 in vitro [141,192], and in a case report [142], likely by blocking the association of the S-protein with membrane-bound ACE2 [41].”
BackgroundAn engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants
Chan, K. K., Tan, T. J. C., Narayanan, K. K., & Procko, E. (2021) · Science Advances · doi:10.1126/sciadv.abf1738 · Cited by 152
Hunt, A. C., Case, J. B., Park, Y., Cao, L., Wu, K., Walls, A. C., Liu, Z., Bowen, J. E., Yeh, A. H.-W., Saini, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1252 · Cited by 127
“This combination of trivalency and receptor mimicry could be a useful general approach for combating viral escape and antigenic drift ( 15 , 24 , 36 , 53 , 63 , 64 ).”
BackgroundSelf-citationPrediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies
Chen, J., Gao, K., Wang, R., & Wei, G. (2021) · Chemical Science · doi:10.1039/d1sc01203g · Cited by 115
Self-citationMechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America
Wang, R., Chen, J., & Wei, G. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c03380 · Cited by 118
Self-citationTao, K., Tzou, P. L., Nouhin, J., Bonilla, H. F., Jagannathan, P., & Shafer, R. W. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00109-21 · Cited by 111
“infected hamsters from weight loss and death (244).”
BackgroundNatural and Experimental SARS-CoV-2 Infection in Domestic and Wild Animals
Meekins, D. A., Gaudreault, N. N., & Richt, J. A. (2021) · Viruses · doi:10.3390/v13101993 · Cited by 118
Omicron BA.2 (B.1.1.529.2): High Potential for Becoming the Next Dominant Variant
Chen, J., & Wei, G. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.2c00469 · Cited by 112
Self-citationChallenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
Cruz-Teran, C. A., Tiruthani, K., McSweeney, M. D., Ma, A. L., Pickles, R. J., & Lai, S. K. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.004 · Cited by 91
Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2
Gao, K., Wang, R., Chen, J., Cheng, L., Frishcosy, J., Huzumi, Y., Qiu, Y., Schluckbier, T., Wei, X., & Wei, G. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00965 · Cited by 95
Self-citationAn update of anti-viral treatment of COVID-19
Yavuz, S. Ş., & Celikyurt, I. K. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2106-250 · Cited by 89
“2d potently neutralized SARS-CoV-2 infection of cells in vitro, and a single intranasal prophylactic dose of decoy protected Syrian hamsters from a subsequent lethal SARS-CoV-2 challenge [32].”
BackgroundEmerging Vaccine-Breakthrough SARS-CoV-2 Variants
Wang, R., Chen, J., Hozumi, Y., Yin, C., & Wei, G. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00557 · Cited by 87
Self-citationOmicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistancePreprint
Chen, J., Wang, R., Gilby, N. B., & Wei, G. (2021) · PubMed · doi:10.48550/arxiv.2112.01318 · Cited by 78
“Last but not least, the correlation between the experimental deep mutational data [15] and our AI-predicted RBD-mutation-induced BFE changes for all possible 3686 RBD mutations on the RBD-ACE2 complex is 0.”
BackgroundMethodSelf-citationGuarra, F., & Colombo, G. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00513 · Cited by 87
Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display
Norman, A. R., Franck, C., Christie, M., Hawkins, P. M. E., Patel, K., Ashhurst, A. S., Aggarwal, A., Low, J. K. K., Siddiquee, R., Ashley, C. L., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01708 · Cited by 77
A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient
Nagy, B., Fejes, Z., Szentkereszty, Z., Sütő, R., Várkonyi, I. Z., Ajzner, É., Kappelmayer, J., Papp, Z., Tóth, A., & Fagyas, M. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.184 · Cited by 76
Persistent Laplacian projected Omicron BA.4 and BA.5 to become new dominating variants
Chen, J., Qiu, Y., Wang, R., & Wei, G. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106262 · Cited by 82
“2 binding to the RBD [26].”
BackgroundMethodResultInfluentialSelf-citationRevealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies
Chen, J., Gao, K., Wang, R., & Wei, G. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167155 · Cited by 76
“Here, we present a validation of our BFE change prediction for mutations on S protein RBD compared to the experimental deep mutations enrichment data [44].”
BackgroundMethodInfluentialSelf-citationAn ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants
Tanaka, S., Nelson, G., Olson, C. A., Buzko, O. V., Higashide, W., Shin, A., Gonzalez, M. R., Taft, J. D., Patel, R. S., Buta, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91809-9 · Cited by 67
Accelerating COVID-19 Research Using Molecular Dynamics Simulation
Padhi, A. K., Rath, S. L., & Tripathi, T. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c04556 · Cited by 67
Lee, C.-Y., & Lowen, A. C. (2021) · Current Opinion in Virology · doi:10.1016/j.coviro.2021.03.009 · Cited by 76
“REGN-COV2 (mAbs) [69] BD-368-2 (mAb) [68] Favipiravir [61] Hydroxychloroquine [61] CV07-209 (mAb) [67] IgG1 ab1 (mAb) [66] hACE2 decoys [63] CC12.”
MethodMarchand, A., Hall‐Beauvais, A. V., & Correia, B. E. (2022) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2022.102370 · Cited by 78
Gawish, R., Starkl, P. M., Pimenov, L., Hladik, A., Lakovits, K., Oberndorfer, F., Cronin, S. J., Ohradanova‐Repic, A., Wirnsberger, G., Agerer, B., et al. (2022) · eLife · doi:10.7554/elife.74623 · Cited by 67
“Moreover, using hamsters (Higuchi et al., 2021; Linsky et al., 2020) and the K18 hACE2 mouse model (Hassler et al., 2021), it has also been shown that different forms of ACE2 can protect from disease, providing – together with our novel murine COVID-19 model – pre-clinical proof-of-concept that…”
MethodOmicron BA.2 (B.1.1.529.2): high potential to becoming the next dominating variantPreprint
Chen, J., & Wei, G. (2022) · Research Square · doi:10.21203/rs.3.rs-1362445/v1 · Cited by 78
“Additionally, SARS-CoV-2 related datasets are the mutational scanning data of the ACE2-RBD complex [3, 4, 30] and the CTC-445.”
Self-citationClinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants
Monteil, V., Eaton, B., Postnikova, E. N., Murphy, M. J., Braunsfeld, B., Crozier, I., Kricek, F., Niederhöfer, J., Schwarzböck, A., Breid, H., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202115230 · Cited by 54
“Thus, blocking Spike/ACE2 binding has become a central strategy of both vaccine design and multiple therapeutic approaches including ACE2-based therapeutics (Linsky et al, 2020; preprint: Svilenov et al, 2020; preprint: Hassler et al, 2021; Higuchi et al, 2021; Tanaka et al, 2021).”
BackgroundThe trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
Rothenberger, S., Hurdiss, D. L., Walser, M., Malvezzi, F., Mayor, J., Ryter, S., Moreno, H., Liechti, N., Bosshart, A., Iss, C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01382-3 · Cited by 80
Next generation of multispecific antibody engineering
Kéri, D., Walker, M., Singh, I., Nishikawa, K. K., & Garcés, F. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad027 · Cited by 65
Self-citationÖz, M., & Lorke, D. E. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111193 · Cited by 57
Advances in developing ACE2 derivatives against SARS-CoV-2
Zhang, H., Lv, P., Jiang, J., Liu, Y., Yan, R., Shu, S., Hu, B., Xiao, H., Cai, K., Yuan, S., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00011-3 · Cited by 57
Zafar, M., Amin, J., Sharif, M., Anjum, M. A., Mallah, G. A., & Kadry, S. (2023) · Mathematics · doi:10.3390/math11020364 · Cited by 56
Rapid characterization of spike variants via mammalian cell surface display
Javanmardi, K., Chou, C., Terrace, C. I., Annapareddy, A., Kaoud, T. S., Guo, Q., Lutgens, J., Zorkic, H., Horton, A. P., Gardner, E. C., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.11.024 · Cited by 56
“Spike is also the primary target for prophylactic and therapeutic neutralizing monoclonal antibodies (nAbs) and ACE2 binding inhibitors (Cao et al., 2020; Chan et al., 2021, 2020; Linsky et al., 2020; Piccoli et al., 2020).”
Sakkiah, S., Guo, W., Pan, B., Ji, Z., Yavaş, G., Azevedo, M. S. P., Hawes, J. J., Patterson, T. A., & Hong, H. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2020.622632 · Cited by 45
“2 was found to tightly bind with the RDB of the trimeric spike protein in four different states (state 1: 1 RBD up, state 2: 2 RBD up, state 3: 1 RBD up and 1 RBD down, and state 4: 2 RBD up and 1 RBD down) (Linsky et al., 2020) which were deposited in the electron microscopy databank and protein data bank, but the st…”
BackgroundEmerging dominant SARS-CoV-2 variants
Chen, J.-H., Wang, R., Hozumi, Y., Liu, G., Qiu, Y., Wei, X.-Q., & Wei, G.-S. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01352 · Cited by 41
Self-citationHassler, L., Wysocki, J. A., Gelarden, I. A., Sharma, I., Τοματσίδου, Α., Ye, M., Gula, H., Nicoleascu, V., Randall, G. C., Pshenychnyi, S., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021091209 · Cited by 45
Classification and Segmentation of Diabetic Retinopathy: A Systemic Review
Shaukat, N., Amin, J., Sharif, M. I., Sharif, M. I., Kadry, S., & Sevcik, L. (2023) · Applied Sciences · doi:10.3390/app13053108 · Cited by 48
Optimization of the antimicrobial peptide Bac7 by deep mutational scanning
Koch, P., Schmitt, S., Heynisch, A., Gumpinger, A., Wuethrich, I., Gysin, M., Shcherbakov, D., Hobbie, S. N., Panke, S., & Held, M. (2022) · BMC Biology · doi:10.1186/s12915-022-01304-4 · Cited by 45
“Discussion DMS methods have been widely applied to study the sequence-activity relationship of proteins [39], optimize enzymes [40], or design therapeutics [41].”
MethodKeep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Chitsike, L., & Duerksen-Hughes, P. J. (2021) · Virology Journal · doi:10.1186/s12985-021-01624-x · Cited by 46
Ferrari, M., Mekkaoui, L., Ilca, F. T., Akbar, Z., Bughda, R., Lamb, K., Ward, K., Parekh, F., Karattil, R., Allen, C. G., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00685-21 · Cited by 38
“Similarly, ACE2-derived 326 inhibitory peptides with improved manufacturability and stability, also showed enhanced SARS327 CoV-2 neutralisation efficacy (25).”
BackgroundBon, C. L., Michon, B., Popot, J., & Zoonens, M. A. (2021) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583521000044 · Cited by 49
Li, M., Li, S., Huang, Y., Chen, H., Zhang, S., Zhang, Z., Wu, W., Zeng, X., Zhou, B., & Li, B. (2021) · Advanced Materials · doi:10.1002/adma.202101707 · Cited by 43
A colorimetric sandwich-type bioassay for SARS-CoV-2 using a hACE2-based affinity peptide pair
Zhu, Q., & Zhou, X. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.127923 · Cited by 40
Amin, J., Anjum, M., Sharif, M., Kadry, S., Nadeem, A., & Ahmad, S. (2022) · Diagnostics · doi:10.3390/diagnostics12040823 · Cited by 38
RetractedSARS-CoV-2 immunity in animal models
Chen, Z., Yuan, Y., Hu, Q., Zhu, A., Chen, F., Li, S., Guan, X., Lv, C., Tang, T., He, Y., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01122-w · Cited by 42
“2d) was found to be protective against SARS-CoV-2 infection [198].”
BackgroundInteraction analyses of SARS-CoV-2 spike protein based on fragment molecular orbital calculations
Akisawa, K., Hatada, R., Okuwaki, K., Mochizuki, Y., Fukuzawa, K., Komeiji, Y., & Tanaka, S. (2021) · RSC Advances · doi:10.1039/d0ra09555a · Cited by 36
Miller, A., Leach, A., Thomas, J. C., McAndrew, C., Bentley, E. M., Mattiuzzo, G., John, L., Mirazimi, A., Harris, G., Gamage, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89957-z · Cited by 35
ACE2‐based decoy receptors for SARS coronavirus 2
Jing, W., & Procko, E. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26140 · Cited by 32
“miniproteins that mimic the SARS-CoV-2 binding epitope on ACE2 have been computationally designed and optimized through rounds of deep mutagenesis and selection.(129,130) These miniproteins have helical structure and share attributes of the ACE2 N-terminal helix that”
MethodResultAnti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic
Vallianou, N. G., Tsilingiris, D., Christodoulatos, G. S., Karampela, Ι., & Dalamaga, Μ. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100096 · Cited by 36
“When administered to Syrian hamsters as a nasal spray, this decoy also prevented severe disease after having received a normally lethal load of SARS-CoV-2 [42].”
BackgroundLi, J., Jia, H., Tian, M., Wu, N., Yang, X., Qi, J., Ren, W., Li, F., & Bian, H. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.869832 · Cited by 35
Exploration of novel αβ-protein folds through de novo design
Minami, S., Kobayashi, N., Sugiki, T., Nagashima, T., Fujiwara, T., Koga, R., Chikenji, G., & Koga, N. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01029-0 · Cited by 40
Havranek, B., Chan, K. K., Wu, A., Procko, E., & Islam, S. M. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00783 · Cited by 33
Kumar, T. H. V., Srinivasan, S., Krishnan, V., Vaidyanathan, R., Babu, K. A., Natarajan, S., & Veerapandian, M. (2022) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2022.133052 · Cited by 33
Williams, A. H., & Zhan, C. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00869 · Cited by 30
Shaukat, N., Amin, J., Sharif, M., Azam, F., Kadry, S., & Krishnamoorthy, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12091454 · Cited by 34
Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidatesPreprint
Walser, M., Rothenberger, S., Hurdiss, D. L., Schlegel, A., Calabro, V., Fontaine, S., Villemagne, D., Paladino, M., Hospodarsch, T., Neculcea, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.25.256339 · Cited by 32
“Here we describe the generation of DARPin molecules - one prominent alternative to antibodies(30) amongst others(31-34) - that bind the SARS-CoV-2 spike protein.”
BackgroundShoemaker, R. H., Panettieri, R. A., Libutti, S. K., Höchster, H. S., Watts, N. R. M., Wingfield, P. T., Starkl, P. M., Pimenov, L., Gawish, R., Hladik, A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271066 · Cited by 30
“Proteins or peptides interacting with either of the binding partners could have therapeutic potential and some very high affinity binders have been reported [8].”
BackgroundFreitas, F. C., Ferreira, P. H. B., Favaro, D. C., & de Oliveira, R. J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01320 · Cited by 30
Watanabe, K., Watanabe, C., Honma, T., Tian, Y., Kawashima, Y., Kawashita, N., Takagi, T., & Fukuzawa, K. (2021) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.1c00663 · Cited by 27
Quantum mechanical simulation of Molnupiravir drug interaction with Si-doped C60 fullerene
Parlak, C., Alver, Ö., & Bağlayan, Ö. (2021) · Computational and Theoretical Chemistry · doi:10.1016/j.comptc.2021.113336 · Cited by 27
Satta, S., Meng, Z., Hernandez, R., Cavallero, S., Zhou, T., Hsiai, T. K., & Zhou, C. (2022) · Theranostics · doi:10.7150/thno.66831 · Cited by 29
“Neutralizing SARS-COV-2 by hACE2 decoys has been proposed as a therapeutic target to ameliorate SARS-CoV-2-stimulated inflammation [11, 46, 51-59].”
BackgroundMolecular-Level Anatomy of SARS-CoV-2 for the Battle against the COVID-19 Pandemic
Komiyama, M. (2021) · Bulletin of the Chemical Society of Japan · doi:10.1246/bcsj.20210030 · Cited by 27
Enzymology and Dynamics by Cryogenic Electron Microscopy
Tsai, M., Wu, W., & Ho, M. (2021) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-100121-075228 · Cited by 30
A dimeric proteomimetic prevents SARS-CoV-2 infection by dimerizing the spike protein
Khatri, B., Pramanick, I., Malladi, S. K., Rajmani, R. S., Kumar, S., Ghosh, P., Sengupta, N., Rahisuddin, R., Kumar, N., Kumaran, S., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01060-0 · Cited by 27
Hampton, J. T., Lalonde, T. J., Tharp, J. M., Kurra, Y., Alugubelli, Y. R., Roundy, C. M., Hamer, G. L., Xu, S., & Liu, W. R. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00565 · Cited by 28
Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein
Zhang, L., Zhang, Y., Qin, X., Jiang, X., Zhang, J., Mao, L., Jiang, Z., Jiang, Y. L., Liu, G., Qiu, J., et al. (2022) · Critical Care · doi:10.1186/s13054-022-04034-9 · Cited by 25
“described a de novo design strategy that allowed them to engineer decoy proteins, namely CTC445, that bind the spike protein of SARS-CoV-2 by replicating the hACE2 interface [57].”
BackgroundMolecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions
Shah, M., & Woo, H. G. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0026 · Cited by 23
“Other groups implemented similar strategies and reported mini-proteins that effectively blocked S–ACE2 binding in pre-clinical investigations (Cao et al., 2020; Linsky et al., 2020).”
Computational Protein Design for COVID-19 Research and Emerging Therapeutics
Kalita, P., Tripathi, T., & Padhi, A. K. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01513 · Cited by 27
Verkhivker, G. M., Agajanian, S., Öztaş, D. Y., & Gupta, G. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00766 · Cited by 22
Zanganeh, S., Goodarzi, N., Doroudian, M., & Movahed, E. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2321 · Cited by 23
“have worked successfully on a similar approach.(124,125) CTC‐445.”
MethodChan, K., Farias, A. G., Lee, H., Guvenc, F., Mero, P., Brown, K. R., Ward, H. N., Billmann, M., Aulakh, K., Astori, A., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12744 · Cited by 27
“Furthermore, mutations in the RBD have appeared among pandemic variants, increasing virus transmissibility and potentially compromising efficacy of currently approved treatments and vaccines [8].”
Socher, E., Conrad, M., Heger, L., Paulsen, F. P., Sticht, H., Zunke, F., & Arnold, P. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30142 · Cited by 25
Xue, T., Wu, W., Guo, N., Wu, C., Huang, J. W., Lai, L., Liu, H., Li, Y., Wang, T., & Wang, Y. (2021) · RSC Advances · doi:10.1039/d1ra00426c · Cited by 21
Comprehensive role of SARS‐CoV‐2 spike glycoprotein in regulating host signaling pathway
Banerjee, S., Wang, X., Du, S., Zhu, C., Jia, Y., Wang, Y., & Cai, Q. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27820 · Cited by 24
Deep learning of protein sequence design of protein–protein interactions
Syrlybaeva, R. R., & Strauch, E. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac733 · Cited by 21
“The Rosetta FastDesign protocol is currently a commonly used protocols for the redesign of AAS demonstrating many experimentally validated designed protein interfaces (Cao et al., 2020; Huang et al., 2016; Jacobs et al., 2016; Linsky et al., 2020; Silva et al., 2019).”
MethodDeep Mutational Scanning of Viral Glycoproteins and Their Host Receptors
Narayanan, K. K., & Procko, E. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.636660 · Cited by 20
Recent Progress Using De Novo Design to Study Protein Structure, Design and Binding Interactions
Ferrando, J., & Solomon, L. A. (2021) · Life · doi:10.3390/life11030225 · Cited by 21
“Linsky and coauthors used a varied approach to create an effective decoy of the An‐ giotensin converting enzyme (ACE2) seen on the cell surface [84].”
MethodDiscovery and development of COVID ‐19 vaccine from laboratory to clinic
Saravanan, V., Chagaleti, B. K., Narayanan, P. L., Anandan, V. B., Manoharan, H., Anjana, G. V., Peraman, R., Namasivayam, S. K. R., Kavisri, M., Arockiaraj, J., et al. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14383 · Cited by 22
“Several studies have demonstrated the effectiveness of Rosetta in improving the stability and immunogenicity of mRNA vaccines (Corbett et al., 2020; Linsky et al., 2020).”
BackgroundApplications of Deep Mutational Scanning in Virology
Burton, T. D., & Eyre, N. S. (2021) · Viruses · doi:10.3390/v13061020 · Cited by 19
Computational Design of Miniproteins as SARS-CoV-2 Therapeutic Inhibitors
Jawad, B., Adhikari, P., Cheng, K., Podgornik, R., & Ching, W. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020838 · Cited by 16
“Besides these concerns, the vaccine candidates and the antibodies rely on the molecular mechanism to interact with pathogens in a way that radically differs from how the pathogen binds its host targets [24].”
Hollenberg, M. D., & Epstein, M. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.12.001 · Cited by 16
“159,160 However, in vivo studies in suitable animal models (to the best of our knowledge) are as yet lacking.”
Repurposing a plant peptide cyclase for targeted lysine acylation
Rehm, F. B. H., Tyler, T. J., Zhou, Y., Huang, Y., Wang, C. K. L., Lawrence, N., Craik, D. J., & Durek, T. (2024) · Nature Chemistry · doi:10.1038/s41557-024-01520-1 · Cited by 17
Shah, M., Moon, S. U., Kim, J. H., Thao, T. T., & Woo, H. G. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.04.030 · Cited by 17
“To overcome this issue, researchers have designed peptide biologics by supplementing helical bundles to stabilize the a 1 helix and effectively inhibit SARS-CoV-2 cell entry [51–52].”
Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variantsPreprint
Rothenberger, S., Hurdiss, D. L., Walser, M., Malvezzi, F., Mayor, J., Ryter, S., Moreno, H., Liechti, N., Bosshart, A., Iss, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.03.429164 · Cited by 17
Kayabolen, A., Akcan, U., Ozturan, D., Polat, H. Ü., Sahin, G. N., Pinarbasi-Degirmenci, N., Bayraktar, C., Soyler, G., Sarayloo, E., Nurtop, E., et al. (2022) · Advancement of science · doi:10.1002/advs.202201294 · Cited by 12
Topological deep learning based deep mutational scanning
Chen, J., Woldring, D., Huang, F., Huang, X., & Wei, G. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107258 · Cited by 16
Self-citationLeach, A., Ilca, F. T., Akbar, Z., Ferrari, M., Bentley, E. M., Mattiuzzo, G., Onuoha, S. C., Miller, A., Ali, H., & Rabbitts, T. H. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105147 · Cited by 16
Dash, P., Mohapatra, S., Ghosh, S., & Nayak, B. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.590154 · Cited by 17
Anti-COVID-19 potential of Azadirachta indica (Neem) leaf extract
Eze, M. O., Ejike, C. E. C. C., Ifeonu, P., Udeinya, I. J., Udenigwe, C. C., & Uzoegwu, P. N. (2022) · Scientific African · doi:10.1016/j.sciaf.2022.e01184 · Cited by 17
Köchl, K., Schopper, T., Durmaz, V., Parigger, L., Singh, A., Krassnigg, A., Cespugli, M., Wu, W. T., Yang, X., Zhang, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-27636-x · Cited by 16
A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infectionPreprint
Hassler, L., Wysocki, J. A., Gelarden, I. A., Τοματσίδου, Α., Gula, H., Nicoleascu, V., Randall, G. C., Henkin, J., Yeldandi, A. V., & BATLLE, D. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.12.435191 · Cited by 15
“There have been recent reports on soluble ACE2 proteins that tested their decoy effect in vitro (13-20).”
BackgroundBreakthroughs in computational design methods open up new frontiers for de novo protein engineering
Meinen, B. A., & Bahl, C. D. (2021) · Protein Engineering Design and Selection · doi:10.1093/protein/gzab007 · Cited by 14
Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Jette, C. A., & Björkman, P. J. (2021) · Viruses · doi:10.3390/v13102106 · Cited by 12
Profiling Levels of Serum microRNAs and Soluble ACE2 in COVID-19 Patients
Elemam, N. M., Hasswan, H., Aljaibeji, H., Sharif‐Askari, N. S., Halwani, R., Taneera, J., & Sulaiman, N. D. (2022) · Life · doi:10.3390/life12040575 · Cited by 13
“Additionally, such a mechanism was suggested by studies using recombinant ACE2 as a protective approach from COVID-19 infection [24,25].”
Background
Metadata
- Authors
- Linsky, T. W., Vergara, R., Codina, N., Nelson, J. W., Walker, M. J., Su, W., Barnes, C. O., Hsiang, T.-Y., Esser-Nobis, K., Yu, K., Reneer, Z. B., Hou, Y. J., Priya, T., Mitsumoto, M., Pong, A., Lau, U. Y., Mason, M. L., Chen, J., Chen, A., Berrocal, T., Peng, H., Clairmont, N. S., Castellanos, J., Lin, Y.-R., Josephson-Day, A., Baric, R. S., Fuller, D. H., Walkey, C. D., Ross, T. M., Swanson, R., Bjorkman, P. J., Gale, M., Blancas-Mejia, L. M., Yen, H.-L., & Silva, D.-A.
- Affiliations
- Neoleukin Therapeutics (United States) (US)
- Neoleukin Therapeutics Inc., Seattle, WA, USA.
- University of Hong Kong (HK)
- California Institute of Technology (US)
- University of Washington (US)
- Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington, Seattle, WA, USA.
- University of Georgia (US)
- University of North Carolina at Chapel Hill (US)
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
- Corresponding author
- Linsky, Thomas W.
- Vergara, Renan
- Nelson, Jorgen W.
- Silva, Daniel-Adriano
- ORCID
- Linsky, Thomas W.
- Vergara, Renan
- Codina, Nuria
- Nelson, Jorgen W.
- Walker, Matthew J.
- Su, Wen
- Barnes, Christopher O.
- Hsiang, Tien-Ying
- Esser-Nobis, Katharina
- Yu, Kevin
- Reneer, Z. Beau
- Hou, Yixuan J.
- Mitsumoto, Masaya
- Lau, Uland Y.
- Mason, Marsha L.
- Chen, Jerry
- Chen, Alex
- Berrocal, Tania
- Peng, Hong
- Josephson-Day, Anna
- Baric, Ralph S.
- Fuller, Deborah H.
- Walkey, Carl D.
- Ross, Ted M.
- Swanson, Ryan
- Bjorkman, Pamela J.
- Gale, Michael
- Blancas-Mejia, Luis M.
- Yen, Hui-Ling
- Silva, Daniel-Adriano
- Venue
- Science
- Published
- 2020-12-04
- Volume
- 370
- Issue
- 6521
- Pages
- 1208-1214
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7920261
- OpenAlex
- W3096331199
- Cited by
- 216
- References
- 72
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 12 · 2023: 33 · 2022: 50 · 2021: 92 · 2020: 10
- FWCI
- 6.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- PubMed Central (submittedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (AI145296, AI127463, R01AI108197)
- National Institute of Allergy and Infectious Diseases (HHSN272201400006C)
- Georgia Research Alliance (GRA-001)
- Neoleukin (UGA-002)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- SARS-CoV-2, de novo protein design, spike protein receptor-binding domain, neutralizing antibodies, decoy receptor, host-directed antiviral therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.